Drug Type Monoclonal antibody |
Synonyms JS 019, JS-019 |
Target |
Mechanism CD39 inhibitors(Ectonucleoside triphosphate diphosphohydrolase 1 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | CN | 23 Jan 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 14 Apr 2022 | |
Lymphoma | Preclinical | CN | 28 Feb 2022 | |
Lymphoma | Preclinical | CN | 28 Feb 2022 | |
Solid tumor | Preclinical | CN | 30 Mar 2021 | |
Solid tumor | Preclinical | CN | 30 Mar 2021 |